Lynparza Blazes PARP Trail In China
AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.
You may also be interested in...
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
Four dozen innovative new drugs are slated to be reviewed under China's fast-track system, including more than 20 products for rare diseases.
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.